导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.68% | 1536/4744 |
| 近一周 | 0.79% | 55/5430 |
| 近一月 | 5.88% | 31/5389 |
| 近一季 | 5.42% | 269/5179 |
| 近半年 | 6.38% | 693/4890 |
| 近一年 | 3.66% | 1870/4340 |
| 近两年 | 41.33% | 1816/2945 |
| 近三年 | 50.63% | 526/2246 |
| 成立以来 | 62.93% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.86% 2931/4961 |
-8.37% 3879/5312 |
- - |
- - |
| 2025 | 11.16% 2762/4813 |
2.64% 1302/3635 |
12.01% 119/4076 |
-8.66% 4056/4524 |
5.86% 396/4813 |
| 2024 | 40.47% 16/3463 |
10.39% 65/2808 |
7.11% 103/3014 |
12.77% 2293/3129 |
5.36% 613/3463 |
| 2023 | -2.04% 553/2656 |
-2.28% 1954/2280 |
2.40% 148/2385 |
4.88% 115/2515 |
-6.66% 1859/2655 |
| 2022 | -3.51% 66/2207 |
2.21% 71/1919 |
-1.26% 1691/2016 |
-7.75% 141/2113 |
3.63% 664/2208 |
| 2021 | 4.43% 577/1822 |
11.49% 23/1255 |
-0.28% 1137/1330 |
-5.89% 875/1466 |
-0.20% 1211/1822 |
| 2020 | 9.65% 840/1250 |
-13.44% 928/1028 |
3.39% 941/1067 |
10.25% 571/1164 |
11.14% 560/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 鹏华中证银行ETF VS. 长安沪深300非周期A(740101) |